EMAIL DIGESTS
Daily
Every morning
Weekly
Sunday recap
Junevity develops novel therapeutics to rewind metabolic disease, targeting upstream regulators of age-related, complex diseases through known pharmacological pathways.
Junevity Raises $10M; Expands Seed Funding to $20M
Junevity Secures $10M Seed Funding Led by Goldcrest and Godfrey Capital